• Erika Jensen-JarolimEmail author
  • Manuel L. Penichet


Infectious diseases, being the major burden in the history of mankind worldwide until the beginning of the twentieth century, were important triggers in the understanding of immunological mechanisms. In contrast to infectious diseases, reports of allergies and cancers were less common but increased tremendously within the last century. Based on the US mortality data of the National Center for Health Statistics, Centers for Disease Control and Prevention 2008, the recent report of the American Cancer Society indicated that the trend of the number of cancer deaths between 1930 and 2007 increased from 100,000 to almost 550,000 per year, with leading causes being lung and bronchus cancer in general, prostate cancer in men, and breast cancer in women. However, depending on the type and site of the malignancy some incidences have decreased.


Atopic Dermatitis Chronic Lymphocytic Leukemia Anaphylactic Reaction Atopic Dermatitis Patient World Allergy Organization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009) Cancer Statistics, 2009. CA Cancer J Clin 59:225–49Google Scholar
  2. 2.
    American Cancer Society (2009) American Cancer Statistics 2009.
  3. 3.
    Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN, and Thun MJ (2003) Long-term trends in cancer mortality in the United States, 1930–1998. Cancer 97:3133–275CrossRefPubMedGoogle Scholar
  4. 4.
    Pearce N and Douwes J (2006) The global epidemiology of asthma in children. Int J Tuberc Lung Dis 10:125–32Google Scholar
  5. 5.
    Sly RM (1999) Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 82:233–48CrossRefPubMedGoogle Scholar
  6. 6.
    Strachan D (2000) Family size, infection and atopy: the first decade of the “hygiene hypothesis”. Thorax 55:2–10CrossRefGoogle Scholar
  7. 7.
    Namazi MR (2007) Extension of the “Hygiene Hypothesis” to the negative association between acne and atopy, hematological malignancies, and malignant melanoma. Medical Hypotheses 69:960–961CrossRefPubMedGoogle Scholar
  8. 8.
    Karhausen LR (2000) Causation: the elusive grail of epidemiology. Med Health Care Philos 3:59–67CrossRefPubMedGoogle Scholar
  9. 9.
    Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, and Calle EE (2005) Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 162:212–21CrossRefPubMedGoogle Scholar
  10. 10.
    Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, Riemer AB, and Gould H (2008) AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 63:1255–66CrossRefPubMedGoogle Scholar
  11. 11.
    Emanuel MB (1988) Hay fever, a post industrial revolution epidemic: a history of its growth during the 19th century. Clinical Allergy 18:295–304CrossRefPubMedGoogle Scholar
  12. 12.
    Biggs JP (1912) London Evidence Against Anti-Toxin (Chapter 107). In: Sanitation Versus vaccination. LeicesterGoogle Scholar
  13. 13.
    Richet CR and Portier P (1902) De l’action anaphylactique de certain venins. Comptes rendus de la Société de biologie, Paris 54:170–2Google Scholar
  14. 14.
    Pirquet C (1906) Allergy. Münchener Medizinische Wochenschrift 53:1457–8Google Scholar
  15. 15.
    Prausnitz C and Kustner H (1921) Studien über die Ueberempfindlichkeit. Zentralbl Bakteriol 86:160–9.Google Scholar
  16. 16.
    Coca AF and Grove EF (1925) A study of the atopic reagins. J Immunol 10:445–64CrossRefGoogle Scholar
  17. 17.
    Scherrer E (1930) The distribution of reagins in the blood plasma. J Allergy 2:467CrossRefPubMedGoogle Scholar
  18. 18.
    Layton LL and Yamanaka E (1962) Demonstration of human reagins to foods, cat dander, an insect, and ragweed and grass pollens. J Allergy 33:271–5CrossRefPubMedGoogle Scholar
  19. 19.
    Augustin R (1967) Demonstration of reagins in the serum of allergic subjects. From WEIR, Handbook of experimental immunology Oxford-Edinburgh: Blackwell, p. 1076Google Scholar
  20. 20.
    Kailin EW, Rossbach EA, and Walzer M (1950) Factors influencing reagin formation in experimental human sensitization to ascaris lumbricoides antigen; the influence of a previous sensitization on rate of sensitization. J Allergy 21:225–31CrossRefPubMedGoogle Scholar
  21. 21.
    Ogilvie BM (1964) Reagin-like antibodies in animals immune to helminth parasites. Nature 204:91–2Google Scholar
  22. 22.
    Zvaifler NJ, Sadun E, and Becker EL (1966) Anaphylactic (reaginic) antibodies in helminthic infections. Clin Res 14:336CrossRefPubMedGoogle Scholar
  23. 23.
    Vaerman JP, Epstein W, Fudenberg H, and Ishizaka K (1964) Direct demonstration of reagin activity in purified gamma 1a globulin. Nature 203:1046–8Google Scholar
  24. 24.
    Augustin R, Connolly R, and Lloyd G (1964) Atopic reagin as a prototype of cytophilic antibodies. Aus: Protides Biol. Fluids, Proc. 11th Coll. Bruges 1963, p. 56, H. Peeters (ed.). Amsterdam: ElseviersCrossRefPubMedGoogle Scholar
  25. 25.
    Felarca AB and Lowell FC (1971) The accumulation of eosinophils and basophils at skin sites as related to intensity of skin reactivity and symptoms in atopic disease. J Allergy Clin Immunol 48:125–33CrossRefPubMedGoogle Scholar
  26. 26.
    Ishizaka K and Ishizaka T (1966) Physicochemical properties of reaginic antibody. 1. Association of reaginic activity with an immunoglobulin other than gammaA- or gammaG-globulin. J Allergy 37:169–85PubMedGoogle Scholar
  27. 27.
    Ishizaka K and Ishizaka T (1967) Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 99:1187–98PubMedGoogle Scholar
  28. 28.
    Johansson SG (1967) Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 2:951–3CrossRefPubMedGoogle Scholar
  29. 29.
    Johansson SG and Bennich H (1967) Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 13:381–94PubMedGoogle Scholar
  30. 30.
    Fishkin BG, Orloff N, Scaduto LE, Borucki DT, and Spiegelberg HL (1972) IgE multiple myeloma: a report of the third case. Blood 39:361–7PubMedGoogle Scholar
  31. 31.
    Carson DA and Metzger H (1974) Interaction of IgE with rat basophilic leukemia cells. IV. Antibody-induced redistribution of IgE receptors. J Immunol 113:1271–7CrossRefPubMedGoogle Scholar
  32. 32.
    Metzger H, Rivnay B, Henkart M, Kanner B, Kinet JP, and Perez-Montfort R (1984) Analysis of the structure and function of the receptor for immunoglobulin E. Mol Immunol 21:1167–73CrossRefPubMedGoogle Scholar
  33. 33.
    Nakajima T and Delespesse G (1986) IgE receptors on human lymphocytes. I. Identification of the molecules binding to monoclonal anti-Fc epsilon receptor antibodies. Eur J Immunol 16:809–14PubMedGoogle Scholar
  34. 34.
    Ludin C, Hofstetter H, Sarfati M, Levy CA, Suter U, Alaimo D, Kilchherr E, Frost H, and Delespesse G (1987) Cloning and expression of the cDNA coding for a human lymphocyte IgE receptor. Embo J 6:109–14PubMedGoogle Scholar
  35. 35.
    Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, and Fallon PG (2004) Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol 173:6346–56CrossRefPubMedGoogle Scholar
  36. 36.
    Martin EG (1935) Predisposing factors and diagnosis of rectal cancer: a discussion of allergy. Ann Surg 102:56–61PubMedGoogle Scholar
  37. 37.
    Bienengraber A (1952) Tumor metastasis in the light of allergology. Zentralbl Chir 77:1873–81PubMedGoogle Scholar
  38. 38.
    Molomut N, Spain DM, Kreisler L, and Warshaw LJ (1955) The effect of an allergic inflammatory response in the tumor bed on the fate of transplanted tumors in mice. Cancer Res 15:181–3CrossRefPubMedGoogle Scholar
  39. 39.
    Berdel W, Nass G, and Wiedemann G (1956) Mechanism of tumor allergy and its importance in tumor pathogenesis. Int Arch Allergy Appl Immunol 9:200–21PubMedGoogle Scholar
  40. 40.
    Loveless M and Cann JR (1955) Distribution of blocking antibody in human serum proteins fractionated by electrophoresis-convection. J Immunol 74:329–39PubMedGoogle Scholar
  41. 41.
    Schlitter HE (1961) Is there an allergy against malignant tumor tissue and what can it signify in regard to the defense of the body against cancer? Strahlentherapie 114:203–24PubMedGoogle Scholar
  42. 42.
    Ebhardt K (1937) Mschr. Krebsbekämpfung: 33Google Scholar
  43. 43.
    Fischer W (1952) Zbl. Path. 89:129Google Scholar
  44. 44.
    Ure DM (1969) Negative association between allergy and cancer. Scott Med J 14:51–4CrossRefPubMedGoogle Scholar
  45. 45.
    McCormick DP, Ammann AJ, Ishizaka K, Miller DG, and Hong R (1971) A study of allergy in patients with malignant lymphoma and chronic lymphocytic leukemia. Cancer 27:93–9CrossRefPubMedGoogle Scholar
  46. 46.
    Augustin R and Chandradasa KD (1971) IgE levels and allergic skin reactions in cancer and non-cancer patients. Int Arch Allergy Appl Immunol 41:141–3CrossRefPubMedGoogle Scholar
  47. 47.
    Jacobs D, Landon J, Houri M, and Merrett TG (1972) Circulating levels of immunoglobulin E in patients with cancer. Lancet 2:1059–61PubMedGoogle Scholar
  48. 48.
    Allegra J, Lipton A, Harvey H, Luderer J, Brenner D, Mortel R, Demers L, Gillin M, White D, and Trautlein J (1976) Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population. Cancer Res 36:3225–6CrossRefPubMedGoogle Scholar
  49. 49.
    Synnerstad I, Fredrikson M, Ternesten-Bratel A, and Rosdahl I (2008) Low risk of melanoma in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 22:1423–8CrossRefPubMedGoogle Scholar
  50. 50.
    Neuchrist C, Kornfehl J, Grasl M, Lassmann H, Kraft D, Ehrenberger K, and Scheiner O (1994) Distribution of immunoglobulins in squamous cell carcinoma of the head and neck. Int Arch Allergy Immunol 104:97–100CrossRefPubMedGoogle Scholar
  51. 51.
    Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, and Bluth MH (2008) Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 153:401–9CrossRefPubMedGoogle Scholar
  52. 52.
    Altrichter S, Kriehuber E, Moser J, Valenta R, Kopp T, and Stingl G (2008) Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol 128:2232–9CrossRefPubMedGoogle Scholar
  53. 53.
    Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, and Gould HJ (2008) Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 57:247–63PubMedGoogle Scholar
  54. 54.
    Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, and Gould HJ (2007) IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179:2832–43CrossRefPubMedGoogle Scholar
  55. 55.
    Gould HJ, Mackay GA, Karagiannis SN, O’Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR, Jr, Joseph M, Capron M, Gilbert M, Murphy GF, and Korngold R (1999) Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 29:3527–37PubMedGoogle Scholar
  56. 56.
    Kershaw MH, Darcy PK, Trapani JA, MacGregor D, and Smyth MJ (1998) Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 10:133–42CrossRefPubMedGoogle Scholar
  57. 57.
    Nagy E, Berczi I, and Sehon AH (1991) Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother 34:63–9CrossRefPubMedGoogle Scholar
  58. 58.
    Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, and Jensen–Jarolim E (2007) Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res 67:3406–11CrossRefPubMedGoogle Scholar
  59. 59.
    Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–57CrossRefPubMedGoogle Scholar
  60. 60.
    Maggon K (2007) Monoclonal antibody “gold rush”. Curr Med Chem 14:1978–87CrossRefPubMedGoogle Scholar
  61. 61.
    Reichert JM and Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349–56CrossRefPubMedGoogle Scholar
  62. 62.
    Jensen-Jarolim E, Untersmayr E, Knittelfelder R, Zielinski CC, Scheiner O, Duschl A, and Riemer AB (2006) Allergo-Oncology: the role of IgE in tumor defense. 26th Symposium of the Collegium Internationale Allergologicum. May 5–10, Malta.Google Scholar
  63. 63.
    Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, and Siccardi AG (2001) IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res 61:5517–22PubMedGoogle Scholar
  64. 64.
    Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, and Gould HJ (2003) Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 33:1030–40CrossRefPubMedGoogle Scholar
  65. 65.
    Bracher M, Gould HJ, Sutton BJ, Dombrowicz D, and Karagiannis SN (2007) Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J Immunol Methods 323:160–71CrossRefPubMedGoogle Scholar
  66. 66.
    Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, and Karagiannis SN (2009) Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 58:915–30CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.IPP-Department of PathophysiologyCenter of Pathophysiology, Infectiology and Immunology, Medical University of ViennaViennaAustria
  2. 2.Division of Surgical Oncology, Department of Surgery and Department of Microbiology, Immunology, and Molecular Genetics, Molecular Biology InstituteJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of CaliforniaLos AngelesUSA

Personalised recommendations